Quantcast
Last updated on April 18, 2014 at 15:29 EDT

Latest Glucagon Stories

2010-04-15 07:41:18

Mass. General, Boston University researchers run first clinical trial of system using 2 hormones An artificial pancreas system that closely mimics the body's blood sugar control mechanism was able to maintain near-normal glucose levels without causing hypoglycemia in a small group of patients. The system, combining a blood glucose monitor and insulin pump technology with software that directs administration of insulin and the blood-sugar-raising hormone glucagon, was developed at Boston...

2010-03-24 15:27:05

DALLAS -- Using leptin alone in place of standard insulin therapy shows promise in abating symptoms of type 1 diabetes, UT Southwestern Medical Center researchers report. UT Southwestern researchers, using mouse models, found that leptin administered instead of insulin showed better management of blood-sugar variability and lipogenesis, the conversion of simple sugars into fatty acids. Leptin is a hormone produced by fat cells and involved in the regulation of body weight. Dr. Roger Unger,...

2010-02-17 07:00:00

INDIANAPOLIS, Feb. 17 /PRNewswire/ -- Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Marcadia plans to initially develop this compound as a treatment for type 2 diabetes with once-weekly dosing. The Phase 1 trial will evaluate MAR701 in healthy volunteers at escalating dose levels. MAR701 targets two peptide...

2009-12-17 17:50:00

MELBOURNE, Australia, Dec. 17 /PRNewswire-FirstCall/ -- Treatment for Diabetic Patients a Major New Objective Key points: *Single injection of proprietary adult stem cells resulted in increased blood insulin levels and sustained reduction in blood glucose levels *Stem cell treatment induced two-fold increase in total numbers of pancreatic islets, and increase in insulin-producing beta cells *Results indicate pancreas may successfully be regenerated by proprietary adult stem cells...

2009-01-27 12:00:00

WYNNEWOOD, Pa., Jan. 27 /PRNewswire/ -- A study released today in Endocrine Practice (2008;14:1075), the leading peer-reviewed journal for practicing endocrinologists in the US and 65 countries, reports a ground breaking discovery with the potential to reverse type 1 and 2 diabetes. Scientists at CureDM, Inc. have identified a 14- amino acid human peptide, Human proIslet Peptide (HIP), consisting of the bioactive region in the human REG3a gene responsible for regenerating pancreatic...

2008-10-15 18:00:08

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today announced that four abstracts summarizing data from the Company's Phase 3 studies of GATTEX(TM) (teduglutide) in patients with short bowel syndrome (SBS) were selected for oral presentations at the 16th United European Gastroenterology Week (UEGW) meeting in Vienna, Austria, October 18-22, 2008, including a presentation of 52-week data from the Phase 3 study of GATTEX in SBS patients. The UEGW is the largest gastroenterology meeting in Europe....

2008-09-17 09:01:00

Oramed Pharmaceuticals, a developer of oral drug delivery systems, has launched preclinical trials of ORMD 0901, a GLP1-analog. Oramed plans to conduct the ORMD 0901 trials at Hadassah University Medical Center and they are expected to conclude by the end of 2008. Oramed plans to launch Phase IIb trials of ORMD 0801, its oral insulin capsule, in India in the first quarter of 2009. ORMD 0901 belongs to the incretin family of drugs which helps to manage diabetes, including reduction in...

2008-09-11 18:00:09

NPS Pharmaceuticals (Nasdaq: NPSP) today reported that data from clinical studies of GATTEX(TM) (teduglutide) in intestinal failure associated with short bowel syndrome will be presented at upcoming medical meetings. At the 30th Congress of the European Society for Clinical Nutrition and Metabolism (ESPEN) taking place in Florence, Italy September 13-16, 2008 clinical data from a 24-week Phase 3 study of GATTEX for short bowel syndrome (SBS) patients who are dependent upon parenteral...

2008-09-09 09:00:09

ROME, Sept. 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a randomized, double-blind, cross-over, four-week head-to-head study demonstrating that BYETTA(R) (exenatide) injection, a GLP-1 receptor agonist, provided significantly lower glucose levels in the post-meal setting when compared to Januvia(TM) (sitagliptin), a DPP-4 inhibitor. Additionally, patients treated with BYETTA reduced post-meal glucagon, showed more...

2005-09-07 16:21:31

La Jolla, CA "“ In many patients with type 2 diabetes, the liver acts like a sugar factory on overtime, churning out glucose throughout the day, even when blood sugar levels are high. Scientists at the Salk Institute for Biological Studies discovered a key cellular switch that controls glucose production in liver cells. This switch may be a potential new target for the development of highly specific diabetes drugs that signal the liver to reduce the production of sugar. The Salk...


Latest Glucagon Reference Libraries

0_0d961f30bdfa64859d9b869b063ddcd2
2010-12-03 18:12:26

Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...

More Articles (1 articles) »